Priority question for written answer P-003851/2020
to the Commission
Rule 138
Tilly Metz (Verts/ALE), **Jutta Paulus** (Verts/ALE), **Margrete Auken** (Verts/ALE), **Pär Holmgren** (Verts/ALE), **Ville Niinistö** (Verts/ALE), **Grace O'Sullivan** (Verts/ALE)

Subject: Access to clinical trial information and transparency in the vaccine strategy

Last week the Commission published its vaccine strategy, but without specifying if and how transparency standards would be upheld in purchase agreements with the industry. Only eleven years ago, and under similar circumstances, EU governments stockpiled Tamiflu, believing it would prevent side effects of the pandemic swine flu, only later realising they had wasted billions on a product with an effect comparable to paracetamol due to lack of access to clinical trial information [1] . The lessons must be learnt from this fiasco. Full access to all clinical trial data is of the utmost importance to be able to ensure the quality, safety and efficacy of any COVID-19 vaccine. The receipt of public funding should be conditional on open science criteria.

1. To avoid any new scandal, will the Commission ensure the full transparency of all clinical data before any COVID-19 vaccine receives market authorisation?

2. What accountability clauses is the Commission planning for the Advance Purchase Agreements to ensure that the industry is held responsible for its products?

[1] Multi-system failure: the story of anti-influenza drugs, BMJ 2014; https://pdfs.semanticscholar.org/e99b/a363bb9235c790870789fb0f67c90ae82018.pdf?_ga=2.192837487.495673763.1592821528-1926250379.1592821528